JP2022525914A5 - - Google Patents

Info

Publication number
JP2022525914A5
JP2022525914A5 JP2021556394A JP2021556394A JP2022525914A5 JP 2022525914 A5 JP2022525914 A5 JP 2022525914A5 JP 2021556394 A JP2021556394 A JP 2021556394A JP 2021556394 A JP2021556394 A JP 2021556394A JP 2022525914 A5 JP2022525914 A5 JP 2022525914A5
Authority
JP
Japan
Prior art keywords
composition according
seq
amino acid
acid sequence
plyss2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525914A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024051 external-priority patent/WO2020198073A1/en
Publication of JP2022525914A publication Critical patent/JP2022525914A/ja
Publication of JP2022525914A5 publication Critical patent/JP2022525914A5/ja
Pending legal-status Critical Current

Links

JP2021556394A 2019-03-22 2020-03-20 感染性心内膜炎を治療する方法 Pending JP2022525914A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962822386P 2019-03-22 2019-03-22
US62/822,386 2019-03-22
US201962832708P 2019-04-11 2019-04-11
US62/832,708 2019-04-11
US201962849093P 2019-05-16 2019-05-16
US62/849,093 2019-05-16
US201962898379P 2019-09-10 2019-09-10
US62/898,379 2019-09-10
US202062965720P 2020-01-24 2020-01-24
US62/965,720 2020-01-24
PCT/US2020/024051 WO2020198073A1 (en) 2019-03-22 2020-03-20 Method of treating infective endocarditis

Publications (2)

Publication Number Publication Date
JP2022525914A JP2022525914A (ja) 2022-05-20
JP2022525914A5 true JP2022525914A5 (enExample) 2023-03-16

Family

ID=72611751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556394A Pending JP2022525914A (ja) 2019-03-22 2020-03-20 感染性心内膜炎を治療する方法

Country Status (11)

Country Link
US (1) US20220160842A1 (enExample)
EP (1) EP3941504A4 (enExample)
JP (1) JP2022525914A (enExample)
KR (1) KR20210141667A (enExample)
CN (1) CN114025782A (enExample)
AU (1) AU2020244764A1 (enExample)
BR (1) BR112021018219A2 (enExample)
CA (1) CA3134154A1 (enExample)
IL (1) IL286389A (enExample)
MX (1) MX2021011469A (enExample)
WO (1) WO2020198073A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023560A1 (en) * 2021-08-17 2023-02-23 Contrafect Corporation New uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863692B1 (ko) * 2006-12-08 2008-10-15 울산대학교 산학협력단 퇴행성질환 및 염증질환에 대한 예방치료 효과를 갖는7-하이드록시-6-메톡시-1,2,3,4-테트라하이드로이소퀴놀린유도체
US9034322B2 (en) * 2011-04-21 2015-05-19 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP2699689A4 (en) * 2011-04-21 2014-12-17 Univ Utrecht Holding Bv STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES
MX389127B (es) * 2012-05-09 2025-03-19 Contrafect Corp Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas.
ES2729123T3 (es) * 2012-05-09 2019-10-30 Contrafect Corp Rotura de biopelícula con lisina plyss2
EP3349780B1 (en) * 2015-09-17 2022-11-09 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria
RU2754667C2 (ru) * 2016-05-12 2021-09-06 Контрафект Корпорейшн Способ микроразбавления в жидкой среде для оценки и определения минимальной ингибирующей концентрации антибактериальных полипептидов
AU2018300062A1 (en) * 2017-07-10 2020-01-30 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof

Similar Documents

Publication Publication Date Title
RU2363489C9 (ru) Способ применения антибиотиков
Raja et al. Daptomycin
JP2022058682A5 (enExample)
JP2022163214A5 (enExample)
RU2020133461A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
Geraci et al. Vancomycin therapy for infective endocarditis
NO320884B1 (no) Anvendelse av lysostafin eller variant derav til fremstilling av et medikament til behandling av infeksjoner.
JPH11508265A (ja) 抗生物質抵抗性グラム陽性細菌の制御および感染治療の方法
JP2012501349A5 (enExample)
IL275795B1 (en) Medical bacteriophage preparations for the treatment of staphylococcus infection
EP1107722B1 (en) A method for the treatment of staphylococcal infection
US10125167B2 (en) Compositions and methods for treating MRSA infections and for sensitizing MRSA to beta-lactam antibiotics
Brauers et al. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations
ES2377016T3 (es) Tioridazina y derivados de la misma para invertir la resistencia a los fármacos anti-microbianos
Eliopoulos et al. Contribution of animal models in the search for effective therapy for endocarditis due to enterococci with high-level resistance to gentamicin
Pittet et al. Infective endocarditis and glycopeptides
Eliopoulos Current and new antimicrobial agents
RU2021127055A (ru) Способ лечения инфекционного эндокардита
JP2022526624A5 (enExample)
Karp et al. Management of infections in neutropenic patients: new opportunities and emerging challenges
CN114615991B (zh) 作为用于抗微生物剂的佐剂的纤维蛋白原和疗法
Zar et al. In vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditis
Dharshini PHARMACOECONOMIC EVALUATION OF VANCOMYCIN AND TEICOPLANIN
Sujatha Drug treatment of MRSA infections.